Clearmind Medicine (CMND) said Thursday its ongoing phase 1/2a clinical trial assessing oral drug candidate CMND-100 in alcohol use disorder has received institutional review board approval from Tel Aviv Sourasky Medical Center in Israel.
The approval will allow patient enrollment at the medical center before the start of the first-in-human trial at the site, the company said.
The company's shares were up 31% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.